Using CogMe technology to prevent and detect delirium in elderly patients
Evaluation of the CogMe Technology Platform for the Prevention and Early Detection of Delirium Among Older Patients in an Acute Hospital Setting: A Proof of Concept Study
This study is testing a new technology called CogMe to see if it can help doctors spot and prevent delirium in older patients who are in the hospital.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 65 Years and up |
| Sex | All |
| Sponsor | Rambam Health Care Campus Academic / other |
| Locations | 1 site (Haifa, North) |
| Trial ID | NCT05311761 on ClinicalTrials.gov |
What this trial studies
This study evaluates the CogMe system, a technological intervention aimed at the early detection and prevention of delirium in elderly patients. It involves collecting physiological and cognitive measurements to assess the system's effectiveness in predicting and identifying delirium. The study targets hospitalized patients aged 65 and older, focusing on those with longer expected hospital stays. By improving early diagnosis, the study aims to enhance clinical outcomes and reduce the complications associated with delirium.
Who should consider this trial
Good fit: Ideal candidates are male and female patients aged 65 years and older who are expected to be hospitalized for 4 days or longer and can provide informed consent.
Not a fit: Patients younger than 65 years or those with existing delirium or cognitive impairments will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly reduce the incidence and impact of delirium in elderly hospitalized patients.
How similar studies have performed: Previous studies have shown that technological interventions can effectively aid in the prevention and detection of delirium, suggesting a promising avenue for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male and female patients aged 65 years of age and older. * Patients with an expected length of hospitalization of 4 days or longer. * Patients who are conscious and cognitively able to provide written informed consent as suggested by a score of 0 on 4AT screening. * Patients who have no diagnosis of delirium prior to enrollment. Exclusion Criteria: * Male and female patients younger than 65 years of age. * Patients with an expected length of hospitalization of less than 4 days. * Patients with uncorrected visual or hearing impairment. * Patients with impaired consciousness or cognitive impairment as determined by a score of 1 or more on 4AT screening.
Where this trial is running
Haifa, North
- Rambam Health Care Campus — Haifa, North, Israel (Recruiting)
Study contacts
- Principal investigator: Tzvi Dwolatzky, MD MBBCh — Rambam Health Care Campus
- Study coordinator: Tzvi Dwolatzky, MD MBBCh
- Email: t_dwolatzky@rambam.health.gov.il
- Phone: +972502061183
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.